The factor VR5O6Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis

Journal of Internal Medicine

Volumn 241, Issue 5, 1997, Pages 379-385

  Svensson, P J ^a   Zoller B ^a   Mattiasson, I ^a   Dahlback B ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

APC resistance; factor V; mutation; protein C; thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5A; PROTEIN C;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; PHLEBOGRAPHY; POINT MUTATION; PRIORITY JOURNAL; RISK FACTOR; SWEDEN; CASE CONTROL STUDY; GENETICS; HETEROZYGOTE DETECTION; MIDDLE AGED; OUTPATIENT; PREVALENCE; RADIOGRAPHY; THROMBOPHLEBITIS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FACTOR V; FACTOR VA; FEMALE; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PHLEBOGRAPHY; POINT MUTATION; PREVALENCE; PROTEIN C; THROMBOPHLEBITIS;

EID: 0030609926     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1997.124140000.x     Document Type: Article

References (29)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
2. Koster T, Rosendaal FR, de Ronde F, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
3. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-21.
4. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
5. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt BL. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1362-3.
6. Voorberg J, Roelse J, Koopman R, Büller H, Berends, F, Ten Cate JW et al. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994; 343: 1535-6.
7. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
8. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270: 4053-7.
9. Zöller B, Holm J, Dahlbäck B. Resistance to activated protein C due to a factor V gene mutation. The most common inherited risk factor of thrombosis. Trends Cardiovasc Med 1996; 6: 45-53.
10. Griffin JH, Evatt BL, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-93.
11. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
12. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
13. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
14. de Stefano V, Leone G. Resistance to activated protein C due to a mutated factor V as a novel cause of inherited thrombophilia. Haematologica 1995; 80: 344-56.
15. Holm J, Zöller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation among myocardial infarction patients and healthy controls higher in Sweden than in other countries. J Intern Med 1996; 239: 221-6.
16. Zöller B, Norlund L, Leksell H, Nilsson J-E, von Schenck H, Rosén U et al. High prevalence of the FV:R506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. Thromb Res 1996; 83: 475-7.
17. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosisprone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
18. Armitage P, Berry G. Statistical Methods in Medical Research. Oxford: Blackwell Scientific Publications, 1994; 131-2.
19. Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22.
20. Ben Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61: 50-4.
21. Heijboer H, Brandjes D, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-6.
22. Tabernero MD, Tomas JF, Alberca I, Orfao A, Borrasca AL, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-254.
23. Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease-critical evaluation of laboratory investigation. Thromb Haemost 1992; 68: 7-13.
24. Koster T, Rosendaal FR, Briét E, Vandermeer FJM, Colly LP. Trienekens PH et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden thrombophilia study). Blood 1995; 85: 2756-61.
25. Norström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
26. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
27. Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter Ch. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-32.
28. Desmarais S, de Moerloose P, Reber G, Minazio P, Perrier A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347: 1374-5.
29. Dahlbäck B. Are we ready for factor V Leiden screening? Lancet 1996; 347: 1346-7.